Hyperion Therapeutics (HPTX) Files $57.5M IPO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts HPTX Hot Sheet
Join SI Premium – FREE
Hyperion Therapeutics (Nasdaq: HPTX) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $57.5 million. Hyperion plans to list on the Nasdaq Global Market under the ticker "HPTX."
The offering is being made through Leerink Swann, Cowen and Company, and Needham & Company.
Hyperion is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.
The offering is being made through Leerink Swann, Cowen and Company, and Needham & Company.
Hyperion is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Recaps Week 7 of NFL Season Impact, Says CapOne Replaced Kalshi at #1 on Finance App Store
- INVO Fertility sets 1-for-4 reverse stock split for Oct. 30
- Gabriel Resources completes second closing of private placement
Create E-mail Alert Related Categories
IPOsRelated Entities
Needham & Company, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
